Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.1 EX-3.1
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 23.3 EX-23.3
- 23.4 EX-23.4
- 23.5 EX-23.5
- 23.6 EX-23.6
- 99.1 EX-99.1
- 99.2 EX-99.2
Vidara Therapeutics International Public similar filings
Filing view
External links
Exhibit 23.5
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated June 25, 2014, with respect to the statements of revenues and direct expenses and related notes thereto of the Actimmune Product Line of InterMune, Inc., included in the Registration Statement on Form S-4 and related prospectus/proxy statement of Vidara Therapeutics International Limited.
| /s/ Ernst & Young LLP |
Redwood City, California
June 25, 2014